Requirements for immune recognition and processing of factor VIII by antigen-presenting cells

Blood Reviews

Volumn 26, Issue 1, 2012, Pages 43-49

  Van Haren, Simon D ^a   Wroblewska, Aleksandra ^a   Fischer, Kathelijn ^b   Voorberg, Jan ^a   Herczenik, Eszter ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antigen presenting cell; Factor VIII; Hemophilia A; Immune response; Inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 8; CD4 ANTIGEN; CELL SURFACE RECEPTOR; COLECALCIFEROL; CYTOKINE; DEXAMETHASONE; LECTIN RECEPTOR; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE RECEPTOR; PHOSPHATIDYLSERINE; RAPAMYCIN; RETROVIRUS VECTOR;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL MEMBRANE TRANSPORT; DENDRITIC CELL; DRUG BINDING SITE; DRUG RECEPTOR BINDING; ENDOCYTOSIS; HEMOPHILIA A; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGEN-PRESENTING CELLS; FACTOR VIII; HEMOPHILIA A; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 83355173939     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2011.10.001     Document Type: Article

References (69)

1. Mannucci P.M., Tuddenham E.G. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001, 344:1773-1779.
2. Lollar P. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX. J Thromb Haemost 2004, 2:1082-1095.
3. Scharrer I., Bray G.L., Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999, 5:145-154.
4. Gouw S.C., van den Berg H.M., le Cessie S., van der Bom J.G. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007, 5:1383-1390.
5. Schwaab R., Brackmann H.H., Meyer C., Seehafer J., Kirchgesser M., Haack A., et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995, 74:1402-1406.
6. Tuddenham E.G., McVey J.H. The genetic basis of inhibitor development in haemophilia A. Haemophilia 1998, 4:543-545.
7. Astermark J., Oldenburg J., Pavlova A., Berntorp E., Lefvert A.K. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006, 107:3167-3172.
8. Astermark J., Oldenburg J., Carlson J., Pavlova A., Kavakli K., Berntorp E., et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006, 108:3739-3745.
9. Astermark J., Wang X., Oldenburg J., Berntorp E., Lefvert A.K. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007, 5:263-265.
10. Peerlinck K., Arnout J., Di Giambattista M., Gilles J.G., Laub R., Jacquemin M., et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997, 77:80-86.
11. Gouw S.C., van der Bom J.G., Auerswald G., Ettinghausen C.E., Tedgard U., van den Berg H.M. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007, 109:4693-4697.
12. Reding M.T., Lei S., Lei H., Green D., Gill J., Conti-Fine B.M. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 2002, 88:568-575.
13. van Helden P.M., van den Berg H.M., Gouw S.C., Kaijen P.H., Zuurveld M.G., Mauser-Bunschoten E.P., et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol 2008, 142:644-652.
14. Fulcher C.A., de Graaf M.S., Zimmerman T.S. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987, 69:1475-1480.
15. Ragni M.V., Bontempo F.A., Lewis J.H. Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC. Transfusion 1989, 29:447-449.
16. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005, 23:975-1028.
17. Burgdorf S., Kurts C. Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol 2008, 20:89-95.
18. Lakadamyali M., Rust M.J., Zhuang X. Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes. Cell 2006, 124:997-1009.
19. Dasgupta S., Repesse Y., Bayry J., Navarrete A.M., Wootla B., Delignat S., et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007, 109:610-612.
20. van Schooten C.J., Shahbazi S., Groot E., Oortwijn B.D., van den Berg H.M., Denis C.V., et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2008, 112:1704-1712.
21. Navarrete A., Dasgupta S., Delignat S., Caligiuri G., Christophe O.D., Bayry J., et al. Splenic marginal zone antigen presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A. J Thromb Haemost 2009, 7:1816-1823.
22. van Haren S.D., Herczenik E., Ten Brinke A., Mertens K., Voorberg J., Meijer A.B. HLA-DR-presented peptide-repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII. Mol Cell Proteomics 2011, 10. M110.002246.
23. Dasgupta S., Navarrete A.M., Bayry J., Delignat S., Wootla B., Andre S., et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci U S A 2007, 104:8965-8970.
24. Lenting P.J., Christophe O.D., Gueguen P. The disappearing act of factor VIII. Haemophilia 2008.
25. Herczenik E, Van Haren SD, Wroblewska A, Kaijen P, van den Biggelaar M, Meijer A, et al. Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain J Allergy Clin Immunol 2011 Sep 29. [Epub ahead of print].
26. Schwarz H.P., Lenting P.J., Binder B., Mihaly J., Denis C., Dorner F., et al. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. Blood 2000, 95:1703-1708.
27. Cunningham N., Laffan M.A., Manning R.A., O'Donnell J.S. Low-density lipoprotein receptor-related protein polymorphisms in patients with elevated factor VIII coagulant activity and venous thrombosis. Blood Coagul Fibrinolysis 2005, 16:465-468.
28. Fischer N., Haug M., Kwok W.W., Kalbacher H., Wernet D., Dannecker G.E., et al. Involvement of CD91 and scavenger receptors in Hsp70-facilitated activation of human antigen-specific CD4(+) memory T cells. Eur J Immunol 2010, 40(4):986-997.
29. Singh S.K., Stephani J., Schaefer M., Kalay H., Garcia-Vallejo J.J., den Haan J., et al. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Mol Immunol 2009, 47:164-174.
30. Dasgupta S., Navarrete A.M., Andre S., Wootla B., Delignat S., Repesse Y., et al. Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation. Haematologica 2008, 93:83-89.
31. Sarafanov A.G., Ananyeva N.M., Shima M., Saenko E.L. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 2001, 276:11970-11979.
32. Villadangos J.A., Ploegh H.L. Proteolysis in MHC class II antigen presentation: who's in charge?. Immunity 2000, 12:233-239.
33. Griffin J.P., Chu R., Harding C.V. Early endosomes and a late endocytic compartment generate different peptide-class II MHC complexes via distinct processing mechanisms. J Immunol 1997, 158:1523-1532.
34. Harding C.V., Geuze H.J. Immunogenic peptides bind to class II MHC molecules in an early lysosomal compartment. J Immunol 1993, 151:3988-3998.
35. Ten Brinke A., Karsten M.L., Dieker M.C., Zwaginga J.J., van Ham S.M. The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. Vaccine 2007, 25:7145-7152.
36. Lutz M.B., Kukutsch N.A., Menges M., Rossner S., Schuler G. Culture of bone marrow cells in GM-CSF plus high doses of lipopolysaccharide generates exclusively immature dendritic cells which induce alloantigen-specific CD4 T cell anergy in vitro. Eur J Immunol 2000, 30:1048-1052.
37. Qadura M., Othman M., Waters B., Chegeni R., Walker K., Labelle A., et al. Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells. J Thromb Haemost 2008, 6:2095-2104.
38. Hay C.R., Ollier W., Pepper L., Cumming A., Keeney S., Goodeve A.C., et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A UKHCDO Inhibitor Working Party. Thromb Haemost 1997, 77:234-237.
39. Oldenburg J., Picard J.K., Schwaab R., Brackmann H.H., Tuddenham E.G., Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997, 77:238-242.
40. Reding M.T., Okita D.K., Diethelm-Okita B.M., Anderson T.A., Conti-Fine B.M. Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII. J Thromb Haemost 2004, 2:1385-1394.
41. Reding M.T., Okita D.K., Diethelm-Okita B.M., Anderson T.A., Conti-Fine B.M. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost 2003, 1:1777-1784.
42. James E.A., van Haren S.D., Ettinger R.A., Fijnvandraat K., Liberman J.A., Kwok W.W., et al. T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site. J Thromb Haemost 2011, 9:689-699.
43. James E.A., Kwok W.W., Ettinger R.A., Thompson A.R., Pratt K.P. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost 2007, 5:2399-2407.
44. Jacquemin M., Vantomme V., Buhot C., Lavend'homme R., Burny W., Demotte N., et al. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood. 2003, 101:1351-1358.
45. Jones T.D., Phillips W.J., Smith B.J., Bamford C.A., Nayee P.D., Baglin T.P., et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost 2005, 3:991-1000.
46. Pfistershammer K., Stockl J., Siekmann J., Turecek P.L., Schwarz H.P., Reipert B.M. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost 2006, 96:309-316.
47. Skupsky J., Zhang A.H., Su Y., Scott D.W. A role for thrombin in the initiation of the immune response to therapeutic Factor VIII. Blood 2009, 114:4741-4748.
48. Qian J., Burkly L.C., Smith E.P., Ferrant J.L., Hoyer L.W., Scott D.W., et al. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol 2000, 30:2548-2554.
49. Reipert B.M., Sasgary M., Ahmad R.U., Auer W., Turecek P.L., Schwarz H.P. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb Haemost 2001, 86:1345-1352.
50. Foy T.M., Aruffo A., Bajorath J., Buhlmann J.E., Noelle R.J. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996, 14:591-617.
51. Honey K., Cobbold S.P., Waldmann H. CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J Immunol 1999, 163:4805-4810.
52. Rossi G., Sarkar J., Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001, 97:2750-2757.
53. Purohit V.S., Ramani K., Sarkar R., Kazazian H.H., Balasubramanian S.V. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex. J Biol Chem 2005, 280:17593-17600.
54. Hoffmann P.R., Kench J.A., Vondracek A., Kruk E., Daleke D.L., Jordan M., et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol 2005, 174:1393-1404.
55. Duffy E.J., Parker E.T., Mutucumarana V.P., Johnson A.E., Lollar P. Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles. J Biol Chem 1992, 267:17006-17011.
56. Meems H., Meijer A.B., Cullinan D.B., Mertens K., Gilbert G.E. Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity. Blood 2009, 114:3938-3946.
57. Novakovic V.A., Cullinan D.C., Wakabayashi H., Fay P., Baleja J.D., Gilbert G.E. Membrane binding properties of the factor VIII C2 domain. Biochem J 2011, 435:187-196.
58. Gregori S. Dendritic cells in networks of immunological tolerance. Tissue Antigens 2011, 77:89-99.
59. Morelli A.E., Thomson A.W. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007, 7:610-621.
60. Hackstein H., Taner T., Zahorchak A.F., Morelli A.E., Logar A.J., Gessner A., et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003, 101:4457-4463.
61. Taner T., Hackstein H., Wang Z., Morelli A.E., Thomson A.W. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005, 5:228-236.
62. Turnquist H.R., Raimondi G., Zahorchak A.F., Fischer R.T., Wang Z., Thomson A.W. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007, 178:7018-7031.
63. Moghimi B., Sack B.K., Nayak S., Markusic D.M., Mah C.S., Herzog R.W. Tolerance induction to factor VIII by transient co-administration with rapamycin. J Thromb Haemost 2011, 9:1524-1533.
64. Rodriguez A., Regnault A., Kleijmeer M., Ricciardi-Castagnoli P., Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999, 1:362-368.
65. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106:255-258.
66. van Helden P.M., Kaijen P.H., Fijnvandraat K., van den Berg H.M., Voorberg J. Factor VIII-specific memory B cells in patients with hemophilia A. J Thromb Haemost 2007, 5:2306-2308.
67. Skupsky J., Zhang A.H., Su Y., Scott D.W. B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells. Mol Ther 2010, 18:1527-1535.
68. Lei T.C., Scott D.W. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 2005, 105:4865-4870.
69. Ngo J.C., Huang M., Roth D.A., Furie B.C., Furie B. Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex. Structure 2008, 16:597-606.